Nano1Health (N1H) is eager to partner with European consortia on groundbreaking projects targeting antimicrobial resistance, zoonotic diseases, and rapid diagnostic tools. Leveraging our expertise in genomics, bioinformatics, and the One Health approach, we strive to enhance pathogen identification and antimicrobial resistance biomarker detection, leading to significant advancements in health and diagnostics.

Nano1Health (N1H) leads the way in genomics innovation, specializing in the rapid characterization of pathogens, microorganisms, and resistance biomarkers from a One Health perspective. Our unique approach, which involves integrating the expertise of veterinarians, geneticists, and bioinformaticians, allows us to address health challenges that intersect humans, animals, and the environment. We focus on zoonotic diseases and antimicrobial resistance, and our state-of-the-art sequencing and bioinformatic analysis capabilities push the boundaries of genomic biomedicine and clinical diagnostics. But what truly sets us apart is our dedication to developing easy-to-use, comprehensive genomic solutions. These solutions transform decentralized genomic analyses into actionable insights, making genomics accessible to all. We also contribute significantly to European consortia focused on antimicrobial resistance and rapid diagnostic tool development, further demonstrating our commitment to the field.